Overview

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2024-11-29

Target enrollment:

Participant gender:

Summary

This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Carboplatin
Paclitaxel
Veliparib